Graph Therapeutics brings total funding to over $10M to advance precision immunology

Graph Therapeutics , a next-generation techbio company developing precision medicines for inflammatory and immune-mediated diseases, has secured a new $5 million investment led by Daphni , the Paris-based venture capital firm. Daphni joins Graph's existing investor syndicate, which includes SquareOne, Merantix Capital, and NAVEC Investment Management. The company has also secured additional non-dilutive funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS